

QIBA PET Amyloid Biomarker Committee (BC) Call

13 April 2018 at 9:00 AM CT

Call Summary

In attendance:			RSNA
<i>Dawn Matthews, MS, MBA (Co-Chair)</i>	Tammie Benzinger, MD, PhD	Adriaan Lammertsma, PhD	Julie Lisiecki
<i>Anne Smith, PhD (Co-Chair)</i>	Rachid Fahmi, MSc, PhD	Nancy Obuchowski, PhD	

Moderator: Ms. Matthews

Profile Updates:

- The Profile will be posted to the wiki after a few edits are made
- Input regarding kinetic modeling from Drs. Lammertsma, Price, and others was greatly appreciated
- Dr. Obuchowski's assistance with clinical application examples was also greatly appreciated; the formulas are not visible as transcribed to the Profile document but Ms. Matthews will address this prior to posting
- It was determined based upon combination of group input and advice from Process committee members that the public comments will be posted, but that names and emails will not be included
- The criteria and limitations for reference studies used in establishing the Claim were noted:
 1. Two studies of three small populations (2 AD, 1 HC) met criteria for short term and alignment with guidelines
 2. Several studies are available using 2-year longitudinal data (caveat on actual accumulation), and comparing reference regions, methods; these were used as an expanded set of reference data to "sanity check" with consideration to clinical trial durations and a larger number of subjects
- The Claim and Clinical Utilization sections of the Profile have been updated and include:
 1. Powering of a clinical trial to measure the rate of amyloid accumulation
 2. Powering of a clinical trial to measure a reduction in the rate of amyloid accumulation (e.g. due to treatment intervention)
 3. Confidence interval around individual percent change
- The Profile is close to being released as consensus (stage 2) and BC members should begin thinking about feasibility/conformance testing of the Profile and contacting possible testing sites that may have ties to ADNI in efforts to promote faster Profile integration within clinical trials
- Profile Appendix H (Phantom) was updated to add missing text, though some questions remain:
 - Appendix H which describes MATLAB script for analysis does not provide the script needed; It was suggested that BioClinica be contacted to see if they might provide the script
 - Appendix H describes the 90 slice Hoffman phantom but does not provide a link to the manufacturer
 - This requires permission from Ron Jaszczak and Bob Koeppe
 - A concern had been expressed regarding unsupervised downloading of the 90 slice phantom image file as details could allow for unauthorized 3D printing of the phantom
 - It was suggested that the Profile provide contact information for the phantom developers and a link to the landing page for the phantom
- Dr. Kinahan is producing a DRO which could be used in place of the physical phantom
- Ms. Matthews to follow up with Dr. Koeppe regarding contact information

Next steps:

- Ms. Matthews to post updated documents to the QIBA wiki, including the following:
 1. An updated clean version of the Profile on the [Profiles](#) page
 2. A working copy of the Profile with tracked changes on the [PET Amyloid BC page](#)
 3. Finalized public comment sheet (without names and emails) on the [PET Amyloid BC page](#)
- BC members will consider any remaining loose ends regarding the phantom section or other sections of the Profile and will prepare for conformance testing
- RSNA staff will begin preparing the e-ballots for voting to publish the Profile as Consensus at the BC and CC levels

NM WebEx Schedule:

04/20	I – 123 Profile TF	05/18	I – 123 Profile TF - <i>TBD</i>
05/04	FDG-PET BC	05/25	NM Leadership - <i>TBD</i>
05/11	PET Amyloid BC	06/12	SPECT TF: TC ^{99m} @ 2pm CT